W Blum

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity
    W Blum
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis Children s Hospital, St Louis, Missouri 63110 1093, USA
    Biol Blood Marrow Transplant 8:608-18. 2002
  2. ncbi request reprint Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study
    William Blum
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110 1093, USA
    Biol Blood Marrow Transplant 9:397-404. 2003
  3. ncbi request reprint Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants
    C Hallemeier
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 10:310-9. 2004
  4. ncbi request reprint Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
  5. ncbi request reprint Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes
    J D Hidalgo
    Division of Oncology, Section of BMT and Leukemia, and Division of Cardiology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 34:615-9. 2004
  6. ncbi request reprint Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
  7. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
  8. ncbi request reprint High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
  9. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
  10. doi request reprint Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity
    W Blum
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis Children s Hospital, St Louis, Missouri 63110 1093, USA
    Biol Blood Marrow Transplant 8:608-18. 2002
    ..Low-dose (550 cGy), single-exposure TBI given at a high dose rate with cyclophosphamide resulted in consistent durable engraftment of HLA-matched sibling PBSC with a low risk of fatal organ toxicity and TRM...
  2. ncbi request reprint Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study
    William Blum
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110 1093, USA
    Biol Blood Marrow Transplant 9:397-404. 2003
    ..Efficacy with TBI conditioning may be reduced compared with high-dose melphalan, but this should be explored in a future trial with a larger cohort of patients...
  3. ncbi request reprint Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants
    C Hallemeier
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 10:310-9. 2004
    ..This low-dose (550 cGy), single-exposure TBI-based regimen resulted in good survival and a low risk of fatal regimen-related organ toxicity in adult patients with AML who underwent unrelated donor bone marrow transplantation in CR...
  4. ncbi request reprint Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
    ..No patient on LDSC GCV exhibited a decline in their ANC below 500/microl and none required growth factors. LDSC GCV is extremely well tolerated and cost-effective as PT for CMV viremia following allo-PBSC transplantation...
  5. ncbi request reprint Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes
    J D Hidalgo
    Division of Oncology, Section of BMT and Leukemia, and Division of Cardiology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 34:615-9. 2004
    ..These arrhythmias are clinically significant, and are a marker for increased mortality and prolonged hospital stay. Additional studies are needed to identify high-risk patients who may benefit from prophylactic anti-arrhythmic therapy...
  6. ncbi request reprint Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
    ..This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population...
  7. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  8. ncbi request reprint High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
    ....
  9. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  10. doi request reprint Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  11. ncbi request reprint Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
    Mark Girgis
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 105:3035-41. 2005
    ..This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM...
  12. ncbi request reprint Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
    Rizwana Chohan
    Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia and Bone Marrow Transplantation, St Louis, MO 63110 1093, USA
    Br J Haematol 123:110-3. 2003
    ..GVHD and/or infection occurred in 54% and were the most common primary causes of death. We conclude that calcineurin inhibitor-induced neurotoxicity is frequently reversible but associated with a poor prognosis...
  13. ncbi request reprint Recent advances in allogeneic hematopoietic stem-cell transplantation
    Steven M Devine
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine
    J Lab Clin Med 141:7-32. 2003
  14. ncbi request reprint High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007
    ..BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM...
  15. ncbi request reprint Post-remission therapy in acute myeloid leukemia: what should I do now?
    William Blum
    Haematologica 93:801-5. 2008
  16. ncbi request reprint Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  17. ncbi request reprint Targeting epigenetic changes in acute myeloid leukemia
    William Blum
    The Ohio State University, Columbus, Ohio, USA
    Clin Adv Hematol Oncol 3:855-65, 882. 2005
    ..In this review, we focus on the clinical applicability of epigenetic targeting in the treatment of patients with AML...
  18. ncbi request reprint Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
    Amy L Hoerr
    School of Medicine, Siteman Cancer Center, Washington University, St Louis, MO, USA
    J Clin Oncol 22:4561-6. 2004
    ..To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL)...
  19. ncbi request reprint Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Cancer 101:1420-7. 2004
    ..Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease...
  20. pmc Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 14:3889-95. 2008
    ....